ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism

Zhe Tian, Keishi Miyata, Tsuyoshi Kadomatsu, Haruki Horiguchi, Hiroyuki Fukushima, Shugo Tohyama, Yoshihiro Ujihara, Takahiro Okumura, Satoshi Yamaguchi, Jiabin Zhao, Motoyoshi Endo, Jun Morinaga, Michio Sato, Taichi Sugizaki, Shunshun Zhu, Kazutoyo Terada, Hisashi Sakaguchi, Yoshihiro Komohara, Motohiro Takeya, Naoki Takeda & 10 others Kimi Araki, Ichiro Manabe, Keiichi Fukuda, Kinya Otsu, Jun Wada, Toyoaki Murohara, Satoshi Mohri, Jun K. Yamashita, Motoaki Sano, Yuichi Oike

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A cardioprotective response that alters ventricular contractility or promotes cardiomyocyte enlargement occurs with increased workload in conditions such as hypertension. When that response is excessive, pathological cardiac remodelling occurs, which can progress to heart failure, a leading cause of death worldwide. Mechanisms underlying this response are not fully understood. Here, we report that expression of angiopoietin-like protein 2 (ANGPTL2) increases in pathologically-remodeled hearts of mice and humans, while decreased cardiac ANGPTL2 expression occurs in physiological cardiac remodelling induced by endurance training in mice. Mice overexpressing ANGPTL2 in heart show cardiac dysfunction caused by both inactivation of AKT and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a signalling and decreased myocardial energy metabolism. Conversely, Angptl2 knockout mice exhibit increased left ventricular contractility and upregulated AKT-SERCA2a signalling and energy metabolism. Finally, ANGPTL2-knockdown in mice subjected to pressure overload ameliorates cardiac dysfunction. Overall, these studies suggest that therapeutic ANGPTL2 suppression could antagonize development of heart failure.

Original languageEnglish
Article number13016
JournalNature Communications
Volume7
DOIs
Publication statusPublished - Sep 28 2016

Fingerprint

Angiopoietins
pathology
Pathology
metabolism
Energy Metabolism
Heart Failure
mice
proteins
Proteins
Reticulum
knockout mice
Calcium-Transporting ATPases
energy
hypertension
endoplasmic reticulum
Workload
Cardiac Myocytes
Knockout Mice
endurance
Cause of Death

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Tian, Z., Miyata, K., Kadomatsu, T., Horiguchi, H., Fukushima, H., Tohyama, S., ... Oike, Y. (2016). ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism. Nature Communications, 7, [13016]. https://doi.org/10.1038/ncomms13016

ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism. / Tian, Zhe; Miyata, Keishi; Kadomatsu, Tsuyoshi; Horiguchi, Haruki; Fukushima, Hiroyuki; Tohyama, Shugo; Ujihara, Yoshihiro; Okumura, Takahiro; Yamaguchi, Satoshi; Zhao, Jiabin; Endo, Motoyoshi; Morinaga, Jun; Sato, Michio; Sugizaki, Taichi; Zhu, Shunshun; Terada, Kazutoyo; Sakaguchi, Hisashi; Komohara, Yoshihiro; Takeya, Motohiro; Takeda, Naoki; Araki, Kimi; Manabe, Ichiro; Fukuda, Keiichi; Otsu, Kinya; Wada, Jun; Murohara, Toyoaki; Mohri, Satoshi; Yamashita, Jun K.; Sano, Motoaki; Oike, Yuichi.

In: Nature Communications, Vol. 7, 13016, 28.09.2016.

Research output: Contribution to journalArticle

Tian, Z, Miyata, K, Kadomatsu, T, Horiguchi, H, Fukushima, H, Tohyama, S, Ujihara, Y, Okumura, T, Yamaguchi, S, Zhao, J, Endo, M, Morinaga, J, Sato, M, Sugizaki, T, Zhu, S, Terada, K, Sakaguchi, H, Komohara, Y, Takeya, M, Takeda, N, Araki, K, Manabe, I, Fukuda, K, Otsu, K, Wada, J, Murohara, T, Mohri, S, Yamashita, JK, Sano, M & Oike, Y 2016, 'ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism', Nature Communications, vol. 7, 13016. https://doi.org/10.1038/ncomms13016
Tian, Zhe ; Miyata, Keishi ; Kadomatsu, Tsuyoshi ; Horiguchi, Haruki ; Fukushima, Hiroyuki ; Tohyama, Shugo ; Ujihara, Yoshihiro ; Okumura, Takahiro ; Yamaguchi, Satoshi ; Zhao, Jiabin ; Endo, Motoyoshi ; Morinaga, Jun ; Sato, Michio ; Sugizaki, Taichi ; Zhu, Shunshun ; Terada, Kazutoyo ; Sakaguchi, Hisashi ; Komohara, Yoshihiro ; Takeya, Motohiro ; Takeda, Naoki ; Araki, Kimi ; Manabe, Ichiro ; Fukuda, Keiichi ; Otsu, Kinya ; Wada, Jun ; Murohara, Toyoaki ; Mohri, Satoshi ; Yamashita, Jun K. ; Sano, Motoaki ; Oike, Yuichi. / ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism. In: Nature Communications. 2016 ; Vol. 7.
@article{bcc12a8f790c4b91b2b3b87afa4276e2,
title = "ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism",
abstract = "A cardioprotective response that alters ventricular contractility or promotes cardiomyocyte enlargement occurs with increased workload in conditions such as hypertension. When that response is excessive, pathological cardiac remodelling occurs, which can progress to heart failure, a leading cause of death worldwide. Mechanisms underlying this response are not fully understood. Here, we report that expression of angiopoietin-like protein 2 (ANGPTL2) increases in pathologically-remodeled hearts of mice and humans, while decreased cardiac ANGPTL2 expression occurs in physiological cardiac remodelling induced by endurance training in mice. Mice overexpressing ANGPTL2 in heart show cardiac dysfunction caused by both inactivation of AKT and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a signalling and decreased myocardial energy metabolism. Conversely, Angptl2 knockout mice exhibit increased left ventricular contractility and upregulated AKT-SERCA2a signalling and energy metabolism. Finally, ANGPTL2-knockdown in mice subjected to pressure overload ameliorates cardiac dysfunction. Overall, these studies suggest that therapeutic ANGPTL2 suppression could antagonize development of heart failure.",
author = "Zhe Tian and Keishi Miyata and Tsuyoshi Kadomatsu and Haruki Horiguchi and Hiroyuki Fukushima and Shugo Tohyama and Yoshihiro Ujihara and Takahiro Okumura and Satoshi Yamaguchi and Jiabin Zhao and Motoyoshi Endo and Jun Morinaga and Michio Sato and Taichi Sugizaki and Shunshun Zhu and Kazutoyo Terada and Hisashi Sakaguchi and Yoshihiro Komohara and Motohiro Takeya and Naoki Takeda and Kimi Araki and Ichiro Manabe and Keiichi Fukuda and Kinya Otsu and Jun Wada and Toyoaki Murohara and Satoshi Mohri and Yamashita, {Jun K.} and Motoaki Sano and Yuichi Oike",
year = "2016",
month = "9",
day = "28",
doi = "10.1038/ncomms13016",
language = "English",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism

AU - Tian, Zhe

AU - Miyata, Keishi

AU - Kadomatsu, Tsuyoshi

AU - Horiguchi, Haruki

AU - Fukushima, Hiroyuki

AU - Tohyama, Shugo

AU - Ujihara, Yoshihiro

AU - Okumura, Takahiro

AU - Yamaguchi, Satoshi

AU - Zhao, Jiabin

AU - Endo, Motoyoshi

AU - Morinaga, Jun

AU - Sato, Michio

AU - Sugizaki, Taichi

AU - Zhu, Shunshun

AU - Terada, Kazutoyo

AU - Sakaguchi, Hisashi

AU - Komohara, Yoshihiro

AU - Takeya, Motohiro

AU - Takeda, Naoki

AU - Araki, Kimi

AU - Manabe, Ichiro

AU - Fukuda, Keiichi

AU - Otsu, Kinya

AU - Wada, Jun

AU - Murohara, Toyoaki

AU - Mohri, Satoshi

AU - Yamashita, Jun K.

AU - Sano, Motoaki

AU - Oike, Yuichi

PY - 2016/9/28

Y1 - 2016/9/28

N2 - A cardioprotective response that alters ventricular contractility or promotes cardiomyocyte enlargement occurs with increased workload in conditions such as hypertension. When that response is excessive, pathological cardiac remodelling occurs, which can progress to heart failure, a leading cause of death worldwide. Mechanisms underlying this response are not fully understood. Here, we report that expression of angiopoietin-like protein 2 (ANGPTL2) increases in pathologically-remodeled hearts of mice and humans, while decreased cardiac ANGPTL2 expression occurs in physiological cardiac remodelling induced by endurance training in mice. Mice overexpressing ANGPTL2 in heart show cardiac dysfunction caused by both inactivation of AKT and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a signalling and decreased myocardial energy metabolism. Conversely, Angptl2 knockout mice exhibit increased left ventricular contractility and upregulated AKT-SERCA2a signalling and energy metabolism. Finally, ANGPTL2-knockdown in mice subjected to pressure overload ameliorates cardiac dysfunction. Overall, these studies suggest that therapeutic ANGPTL2 suppression could antagonize development of heart failure.

AB - A cardioprotective response that alters ventricular contractility or promotes cardiomyocyte enlargement occurs with increased workload in conditions such as hypertension. When that response is excessive, pathological cardiac remodelling occurs, which can progress to heart failure, a leading cause of death worldwide. Mechanisms underlying this response are not fully understood. Here, we report that expression of angiopoietin-like protein 2 (ANGPTL2) increases in pathologically-remodeled hearts of mice and humans, while decreased cardiac ANGPTL2 expression occurs in physiological cardiac remodelling induced by endurance training in mice. Mice overexpressing ANGPTL2 in heart show cardiac dysfunction caused by both inactivation of AKT and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a signalling and decreased myocardial energy metabolism. Conversely, Angptl2 knockout mice exhibit increased left ventricular contractility and upregulated AKT-SERCA2a signalling and energy metabolism. Finally, ANGPTL2-knockdown in mice subjected to pressure overload ameliorates cardiac dysfunction. Overall, these studies suggest that therapeutic ANGPTL2 suppression could antagonize development of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=84989235444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989235444&partnerID=8YFLogxK

U2 - 10.1038/ncomms13016

DO - 10.1038/ncomms13016

M3 - Article

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 13016

ER -